Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure

[1]  J. Jordan,et al.  Direct Renin Inhibition With Aliskiren in Obese Patients With Arterial Hypertension , 2007, Hypertension.

[2]  B. Oh,et al.  Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. , 2007, Journal of the American College of Cardiology.

[3]  A. Stanton,et al.  Aliskiren Reduces Blood Pressure and Suppresses Plasma Renin Activity in Combination With a Thiazide Diuretic, an Angiotensin-Converting Enzyme Inhibitor, or an Angiotensin Receptor Blocker , 2007, Hypertension.

[4]  Roland E Schmieder,et al.  Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. , 2007, American journal of hypertension.

[5]  J. Staessen,et al.  Oral renin inhibitors , 2006, The Lancet.

[6]  R. Schmieder,et al.  Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients , 2005, Circulation.

[7]  A. Stanton,et al.  Blood Pressure Lowering in Essential Hypertension With an Oral Renin Inhibitor, Aliskiren , 2003, Hypertension.

[8]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[9]  V. Oberhauser,et al.  Effects of angiotensin-(1-7) and other bioactive components of the renin–angiotensin system on vascular resistance and noradrenaline release in rat kidney , 2003, Journal of hypertension.

[10]  N. Hollenberg.  Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril. , 2002, Current hypertension reports.

[11]  A. Pessina,et al.  Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases , 2002, Journal of hypertension.

[12]  G. Wuerzner,et al.  Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100): Comparison With Enalapril , 2002, Hypertension.

[13]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[14]  J. Connell,et al.  Vasoconstrictor Effect of the Angiotensin-Converting Enzyme–Resistant, Chymase-Specific Substrate [Pro11D-Ala12] Angiotensin I in Human Dorsal Hand Veins: In Vivo Demonstration of Non-ACE Production of Angiotensin II in Humans , 2001, Circulation.

[15]  J. Connell,et al.  Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. , 2001, Journal of the American College of Cardiology.

[16]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[17]  M. Cooper,et al.  Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy. , 1999, Hypertension.

[18]  S. Pringle,et al.  How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? , 1999, Heart.

[19]  J. McMurray,et al.  Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: implications for clinical practice , 1997, Heart.

[20]  A. Dominiczak,et al.  Plasma angiotensin II, predisposition to hypertension, and left ventricular size in healthy young adults. , 1996, Circulation.

[21]  M B Weiss,et al.  Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. , 1996, American heart journal.

[22]  J. Reid,et al.  Responses to an Orally Active Renin Inhibitor, Remikiren (Ro 42–5892), After Controlled Salt Depletion in Humans , 1995, Journal of cardiovascular pharmacology.

[23]  S. Yusuf,et al.  Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction. , 1994, American heart journal.

[24]  E. Fleck,et al.  Hemodynamic and Neurohormonal Effects of the Angiotensin II Antagonist Losartan in Patients With Congestive Heart Failure , 1993, Circulation.

[25]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[26]  M. Packer,et al.  Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure. , 1991, The American journal of cardiology.

[27]  K. Misono,et al.  Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. , 1990, The Journal of biological chemistry.

[28]  A. J. Man in 't Veld,et al.  Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension. , 1990, BMJ.

[29]  H. Glassman,et al.  Prolonged Duration of Blood Pressure Response to Enalkiren, the Novel Dipeptide Renin Inhibitor, in Essential Hypertension , 1990, Hypertension.

[30]  A. Delabays,et al.  Hemodynamic and Humoral Effects of the New Renin Inhibitor Enalkiren in Normal Humans , 1989, Hypertension.

[31]  J. Rush,et al.  Tolerability of enalapril in congestive heart failure. , 1989, The American journal of cardiology.

[32]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[33]  N. Choudry,et al.  Increased cough reflex associated with angiotensin converting enzyme inhibitor cough. , 1987, British medical journal.